A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms
Psychopharmacology Bulletin · 12.08.2025 · 50 (3) · 76-96
DOI: 10.64719/pb.4615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 12.08.2025. Verfasst von Ivan Urits und 10 weiteren Autor:innen. Beteiligte Einrichtung: Urits, MD, Berger, MD, PhD, Hasoon, MD, Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose of Review This is a comprehensive review of the literature regarding the use of Lofexidine for opiate withdrawal symptoms. It covers the background and necessity of withdrawal programs and the management of withdrawal symptoms and then covers the existing evidence of the use of Lofexidine for this purpose. Recent Findings Opiate abuse leads to significant pain and suffering. However, withdrawal is difficult and often accompanied by withdrawal symptoms and renewed cravings. These symptoms are driven mostly by signaling in the locus coeruleus and the mesolimbic system and a rebound increase in noradrenaline, producing symptoms such as anxiety, gastrointestinal upset, and tension. Lofexidine, an alpha-2 agonist, can be used to manage acute withdrawal symptoms before starting maintenance treatment with either methadone or buprenorphine. Lofexidine, if FDA approved for management of withdrawal symptoms and has been proved to be both effective and safe. Summary Opiate addiction is increasing and plaguing the western world and specifically the U.S. It takes a large toll on both a personal and societal level and carries a high cost. Withdrawal is difficult, both related to withdrawal symptoms and renewed cravings. Lofexidine has been shown to be effective in reducing the former and could potentially aid in recovery and withdrawal.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urits, MD, Berger, MD, PhD, Hasoon, MD, Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA. Patel, Won Jung, Georgetown University Sc…
Zitieren
APA
Urits, I., Patel, A., Zusman, R., Virgen, C. G., Mousa, M., Berger, A. A., Kassem, H., Jung, J. W., Hasoon, J., Kaye, A. D., & Viswanath, O. (2025). A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms. Psychopharmacology Bulletin, 50(3), 76-96. https://doi.org/10.64719/pb.4615
Vancouver
Urits I, Patel A, Zusman R, Virgen CG, Mousa M, Berger AA, et al. A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms. Psychopharmacology Bulletin. 2025;50(3):76-96. doi:10.64719/pb.4615
BibTeX
@article{Urits2025,
author = {Urits, Ivan and Patel, Anjana and Zusman, Robbie and Virgen, Celina Guadalupe and Mousa, Mohammad and Berger, Amnon A and Kassem, Hisham and Jung, Jai Won and Hasoon, Jamal and Kaye, Alan D and Viswanath, Omar},
title = {A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms},
journal = {Psychopharmacology Bulletin},
year = {2025},
volume = {50},
number = {3},
pages = {76--96},
doi = {10.64719/pb.4615}
}
EUVIMED